QT Quince Therapeutics, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)Follow the Quince Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €29.5m. The latest transaction was filed on 29 December 2025 (J). Among the most active insiders: Thye Dirk. All data is free.
€568,671
12 ops.
Buy Volume
€148,942
2 ops.
Sell Volume
Analyst consensus: bullish or bearish? Analysts rate Quince Therapeutics, Inc. Buy (bullish), based on 4 analysts. Average price target: US$82.75.
Buys €568,671 €148,942 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 29 December 2025
All Executives24 Thresholds0 Prospectus0 Other0
Declarations 24 total
● Director · Executives · 23 Oct 2024
8,918 shares Common Stock SEC:0000912282-25-001468:0
▼ Director · Executives · 26 Dec 2025
50,000 shares @ US$3.47 100.0% of flow Common Stock SEC:0000912282-25-001469:0
● CEO and CMO · Executives · 10 Dec 2025
739,885 shares 0Common Shares SEC:0000912282-25-001407:0
◇ CBO, COO & CCO · Executives · 5 Dec 2025
2,271 shares @ US$0.55 0.7% of flow Common Shares SEC:0000912282-25-001370:0
◆ CBO, COO & CCO · Executives · 18 Jun 2025
37,736 shares @ US$1.20 26.5% of flow Common Shares SEC:0000912282-25-000697:0
◆ President · Executives · 18 Jun 2025
7,548 shares @ US$1.20 21.8% of flow Common Shares SEC:0000912282-25-000696:0
◆ CEO and CMO · Executives · 18 Jun 2025
150,944 shares @ US$1.20 35.6% of flow Common Shares SEC:0000912282-25-000695:0
▲ CEO AND CHIEF MEDICAL OFFICER · Executives · 29 Aug 2024
77,500 shares @ US$0.69 16.9% of flow Common Stock SEC:0001415889-24-022702:0
Canonical exit: 27 Nov 2024 (T+90) ▲ PRESIDENT · Executives · 20 Aug 2024
48,387 shares @ US$0.65 100.0% of flow Common Stock SEC:0001415889-24-022054:0
Canonical exit: 18 Nov 2024 (T+90) ▲ CHIEF BUSINESS OFFICER AND COO · Executives · 19 Aug 2024
2,155 shares @ US$0.58 1.0% of flow Common Stock SEC:0001415889-24-021869:0
Canonical exit: 17 Nov 2024 (T+90) ◇ CHIEF BUSINESS OFFICER AND COO · Executives · 4 Jun 2024
56,061 shares @ US$0.55 25.9% of flow Common Stock SEC:0001415889-24-015533:0
◇ CHIEF EXECUTIVE OFFICER · Executives · 16 Jan 2024
90,531 shares @ US$0.55 15.9% of flow Common Stock SEC:0001415889-24-001313:0
▲ Director · Executives · 12 Dec 2023
300 shares @ US$1.00 0.1% of flow Common Stock SEC:0001209191-23-058694:0
Canonical exit: 11 Mar 2024 (T+90) ▲ Director · Executives · 5 Dec 2023
19,123 shares @ US$1.01 8.5% of flow Common Stock SEC:0001209191-23-057799:0
Canonical exit: 4 Mar 2024 (T+90) ▲ Director · Executives · 29 Nov 2023
14,378 shares @ US$0.98 6.1% of flow Common Stock SEC:0001209191-23-057053:0
Canonical exit: 27 Feb 2024 (T+90) ▲ Director · Executives · 30 Aug 2023
41,026 shares @ US$1.31 23.3% of flow Common Stock SEC:0001209191-23-047880:0
Canonical exit: 28 Nov 2023 (T+90) ▲ Director · Executives · 15 Aug 2023
107,886 shares @ US$1.32 62.0% of flow Common Stock SEC:0001209191-23-046402:0
Canonical exit: 13 Nov 2023 (T+90) ▲ Chief Executive Officer · Executives · 10 Aug 2023
88,000 shares @ US$1.26 35.4% of flow Common Stock SEC:0001209191-23-045432:0
Canonical exit: 8 Nov 2023 (T+90) ▲ Chief Executive Officer · Executives · 8 Aug 2023
80,000 shares @ US$1.24 31.7% of flow Common Stock SEC:0001209191-23-045235:0
Canonical exit: 6 Nov 2023 (T+90) ▲ Chief Business Officer · Executives · 8 Aug 2023
71,762 shares @ US$1.22 73.1% of flow Common Stock SEC:0001209191-23-045234:0
Canonical exit: 6 Nov 2023 (T+90) ▲ Director · Executives · 8 Aug 2023
8,000 shares @ US$1.23 100.0% of flow Common Stock SEC:0001209191-23-045231:0
Canonical exit: 6 Nov 2023 (T+90) ▼ Chief Accounting Officer & VP · Executives · 6 Mar 2023
1,871 shares @ US$0.98 32.2% of flow Common Stock SEC:0001209191-23-016507:0
● Chief Accounting Officer & VP · Executives · 5 Dec 2022
1,640 shares @ US$0.72 20.9% of flow Common Stock SEC:0001209191-22-060218:0
● Chief Accounting Officer & VP · Executives · 6 Sept 2022
1,520 shares @ US$1.64 47.0% of flow Common Stock SEC:0001209191-22-049221:0
关于 Quince Therapeutics, Inc. Quince Therapeutics, Inc. 是一家生物制药公司，专注于开发神经退行性疾病的治疗方法。它采用创新方法来提高患者的生活质量。